<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The presence of occult disease in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients after therapy is one of the major problems faced by oncologists </plain></SENT>
<SENT sid="1" pm="."><plain>For example, although 95% of pediatric T-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e>) patients have a complete therapeutic response to multiagent chemotherapy, half will relapse, indicating that they must have harbored low levels of <z:e sem="disease" ids="C0242594" disease_type="Neoplastic Process" abbrv="">residual cancer</z:e> cells at the end of therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Sensitive detection assays promise to help identify those patients that carry this <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) and are at risk of relapse </plain></SENT>
<SENT sid="3" pm="."><plain>We have developed and validated a quantitative polymerase chain reaction (PCR) assay targeting <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific chromosomal rearrangements, including del(1) involving the <z:chebi fb="114" ids="37710">tal</z:chebi>-1 locus in pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> and t(14;18) involving the bcl-2 locus in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>This quantitative PCR assay utilizes a synthetic internal calibration standard (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICS</z:e>) that contains priming sequences identical to those found flanking the chromosomal rearrangement breakpoints </plain></SENT>
<SENT sid="5" pm="."><plain>Using this <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICS</z:e>-PCR method, the limits of detection were 5 tumor cells at ratios of 1 tumor cell in 10(5) <z:mpath ids='MPATH_458'>normal</z:mpath> cells and a linear range up to 100% <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="6" pm="."><plain>This <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICS</z:e>-PCR method has also performed well in terms of precision and accuracy as indicated by low coefficients of variation, minimal random, proportional, and constant errors, and good clinical sensitivity and specificity characteristics </plain></SENT>
<SENT sid="7" pm="."><plain>This technique will allow for the evaluation of parameters such as the rate of therapeutic response and the levels of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> as predictors of patient outcome </plain></SENT>
</text></document>